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bstract
ntroduction. – Tumour necrosis factor alpha (TNF) has emerged as a therapeutic target in chronic inflammatory disorders characterised by a
h1 type immune response, such as rheumatoid arthritis (RA). The presence of allergic disease in these patients could be influenced both by the
resence of RA and anti-TNF therapy. Our aim was to evaluate the prevalence of sensitisation to airborne allergens and allergic disease in RA
atients, with and without anti-TNF treatment.
ethods. – RA patients with (N = 20) and without (N = 20) anti-TNF therapy (groups T and R) were enrolled. Healthy controls (N = 60, group C)
ere randomly selected from the general population. All participants answered a standardised questionnaire to assess the prevalence of allergic
isease and had skin prick tests (SPT) with a standard panel of airborne allergen extracts.
esults. – Significant differences were found in the prevalence of positive SPT between groups T and R (70% vs 35%, p = 0.027) and groups T and
(70% vs 36.7%, p = 0.009), but not between groups R and C. The prevalence of allergic disease was similar in the three groups. Groups T and
had similar gender and age distribution, disease duration, disease activity score (DAS28), erythrocyte sedimentation rate and serum C-reactive
rotein.
onclusions. – Increased prevalence of sensitisation to airborne allergens in RA patients treated with anti-TNF was found. The clinical impact
f the positive SPT following anti-TNF initiation has now to be assessed.
2009 Société franc¸aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.
D
o
a
o
f
v
a
p
geywords: TNF; Rheumatoid arthritis; Autoimmunity; Atopy; Allergy
. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disorder
hose underlying cause is still unclear. T cell involvement in
he pathogenesis of RA is unquestionable. Their role is demon-
trated by the presence of activated CD4 + and CD8 + T cells in
he synovial fluid and lining tissue of RA inflamed joints [1].
Until recently, the adaptative cellular immune response has
een characterized broadly by two functional subsets of CD4 +Please cite this article in press as: Machado P, et al. Increased prevalence
anti-TNF. Joint Bone Spine (2009), doi:10.1016/j.jbspin.2009.01.007
cells, which can be distinguished according to their cytokine
ecretion profiles [2]. Each subset, T helper type 1 (Th1) and T
elper type 2 (Th2), regulates the other in a dynamic process.
∗ Corresponding authors.
E-mail addresses: pedrommcmachado@gmail.com (P. Machado),
lexandrafigueirasantos@gmail.com (A. Santos).
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oi:10.1016/j.jbspin.2009.01.007ifferent disease manifestations are associated with prominence
f one or the other of Th1 or Th2 phenotypes [3]. RA is gener-
lly thought to be a Th1 disease, T cell clones from synovium
r peripheral blood having a Th1-like phenotype [4]. T cells
rom joints affected by RA produce large amounts of IFN- but
ery small amounts of interleukin (IL)-4, and synovitis is associ-
ted with lack of the IL-4 gene [5,6]. Atopy, defined as a genetic
ropensity to develop IgE antibodies in response to specific aller-
ens, results from a Th2 type response, with T cells producing
he IgE-switching cytokines IL-4 and IL-13 [7]. Atopy can be
ssessed by skin prick tests (SPT) or determination of serum spe-
ific IgE. It is a well-established risk factor for allergic diseases,
uch as asthma, rhinitis and atopic eczema [8].of allergic sensitisation in rheumatoid arthritis patients treated with
Tumour necrosis factor alpha (TNF) is a pleiotropic
ytokine that has emerged as a therapeutic target in chronic
nflammatory disorders characterised by a Th1 type immune
esponse, such as RA, in which TNF is generated in excess [9].
by Elsevier Masson SAS. All rights reserved.
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NF belongs to a family of peptide ligands that activate a corre-
ponding set of structurally related receptors [10]. It is produced
y several pro-inflammatory cells (mainly macrophages, but also
onocytes, dendritic cells, B cells, CD4 + T cells, neutrophils,
ast cells and eosinophils) and structural cells (fibroblasts,
pithelial cells and smooth muscle cells). It is an important
ytokine of the innate immune response, but its biological func-
ion also includes the modulation of growth differentiation and
roliferation of a variety of cell types and it is also important
n apoptosis [11]. Besides these effects, TNF is a well-known
nducer of the inflammatory response and a regulator of immu-
ity. Its inflammatory properties are classically mediated by
eans of a wide variety of pro-inflammatory cytokines, includ-
ng IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, interferon gamma
IFN-) and transforming growth factor- (TGF-), generated
ainly through nuclear factor B (NF-B) activation [11].
The development of Th2 type disorders in RA patients treated
ith anti-TNF agents could therefore be influenced not only
y the presence of RA but also by the anti-TNF therapy itself.
e conducted a case–control study to evaluate the prevalence
f sensitisation to airborne allergens and allergic disease in RA
atients, with and without anti-TNF treatment, and in healthy
ontrols. Our results demonstrate, for the first time, an increased
revalence of sensitisation to airborne allergens in RA patients
reated with anti-TNF.
. Methods
.1. Patients
This case-control study was conducted between July and
ecember 2007 and enrolled 20 RA patients with anti-TNF
herapy and 20 RA patients without anti-TNF therapy, con-
ecutively observed in the Rheumatology Department. RA was
efined according to the American College of Rheumatol-
gy (formerly, the American Rheumatism Association) revised
riteria. Disease activity score (DAS28) [12], erythrocyte
edimentation rate (ESR), C-reactive protein (CRP), disease
uration and current treatment (including dosages and dura-
ion of therapy) were recorded. Eosinophil peripheral blood
ount (Eos) and serum total IgE (IgE) were determined in
ll RA patients. IgE (UI/L) was determined using the neph-
lometry technique. Healthy controls (N = 60) were randomly
elected from the general population. Informed consent was
btained from all patients and controls previously to enrol-
ent.
.2. Questionnaire
All patients and controls answered a standardised question-
aire validated in Portuguese to assess the prevalence of allergic
isease [13]. The allergic disorders considered in the question-
aire were asthma, allergic rhinitis and atopic eczema, althoughPlease cite this article in press as: Machado P, et al. Increased prevalence
anti-TNF. Joint Bone Spine (2009), doi:10.1016/j.jbspin.2009.01.007
t included a final broad question on any kind of diagnosed aller-
ic disease, namely food, drug and venom allergy. The positive
nswers were systematically checked with a detailed clinical
istory by the same investigator (AS). Prevalence concerned
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nly those subjects with clinical symptoms at the time or in the
revious 12 months of the study.
.3. Skin prick testing
All patients and controls underwent SPT with a standard
anel of airborne allergen extracts, which included the Ga2len
an-European Standard SPT Panel [14]. SPT were performed
ith a standardised procedure, on the volar surface of the non-
ominant side forearm. Saline 0.9% was used as a negative
ontrol and histamine (concentration of 10 mg/ml of saline) was
sed as a positive control. SPT results in all patients and controls
ere assessed by one of two experienced blinded allergy nurses
5 minutes later. Weal diameters were measured as the mean of
wo perpendicular diameters including the widest one. A weal
iameter greater or equal to 3 mm as opposed to the negative
ontrol was considered a positive result.
.4. Statistical analysis
Descriptive characteristics of the study population were tab-
lated as median and interquartile range, or proportions as
pplicable. Groups T, R and C were statistically compared using
ruskal-Wallis, Mann-Whitney U and Chi2 tests, as appropri-
te. Significance was determined using a two-sided  level of
.05. Statistical analysis was performed using SPSS 14.0 for
indows.
. Results
Our study population included 20 RA patients with anti-
NF therapy (group T – 13 patients treated with 3 mg/kg of
nfliximab every eight weeks, five with 40 mg of adalimumab
very two weeks and two with 50 mg of etanarcept every
eek), 20 RA patients without anti-TNF therapy (group R) and
0 healthy controls (group C). Table 1 summarizes the descrip-
ive characteristics of the patients study cohort, according to the
reatment group. Comparing groups T and R, there were no sta-
istically significant differences in gender and age distribution,
uration of the disease, DAS28, ESR or CRP.
All patients were taking doses of prednisolone less than or
qual to 7.5 mg per day (or equivalent). Although there were
o differences regarding the proportion of patients taking pred-
isolone and methotrexate, the dosages of both medications
ere higher in group R compared to group T. In group R, there
ere significantly more patients on hydroxychloroquine and sul-
asalazine. Median (IQR) anti-TNF therapy duration in group
was 24.5 (9.75–46.5) months.
Table 2 compares groups of RA patients and controls regard-
ng age, prevalence of allergic disease, proportion of participants
ith positive SPT, Eos and serum total IgE. A higher prevalence
f positive SPT was found in group T compared to group R
p = 0.027, Chi2) and in group T compared to group C (p = 0.009,of allergic sensitisation in rheumatoid arthritis patients treated with
hi2). There were no differences in the prevalence of posi-
ive SPT when comparing groups R and C (p = 0.893, Chi2).
he prevalence of allergic disease according to the question-
aire was similar in the three groups. No differences were found
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Table 1
Summary and comparison of the RA descriptive characteristics of the study cohort according to the treatment group (n = 40).
RA patients with anti-TNF
(group T, n = 20)
RA patients without anti-TNF
(group R, n = 20)
p-value
Age – years, median (IQR) 54.50 (50.25–61.50) 58.00 (42.25–69.75) p = 0.189
Gender – female, n (%) 18 (90.00) 17 (85.00) p = 1.000
Disease duration – years, median (IQR) 10.00 (6.50–15.00) 17.00 (4.75–20.00) p = 0.355
DAS28 – median (IQR) 3.07 (2.41–4.18) 2.57 (1.67–3.36) p = 0.142
ESR (mm/1h) – median (IQR) 15.00 (7.75–42.75) 13.00 (8.00–26.75) p = 0.565
CRP (mg/dl) – median (IQR) 0.5 (0.36–1.10) 0.72 (0.43–1.93) p = 0.383
Current medication – n (%)
Prednisolone 15 (75.00) 16 (80.00) p = 0.705
Methotrexate 15 (75.00) 18 (90.00) p = 0.212
Sulfasalazine 1 (5.00) 8 (40.00) p= 0.008
Hydroxychloroquine 2 (10.00) 13 (65.00) p< 0.001
Current dose of medication – median (IQR)
Prednisolone (mg/day)
Methotrexate (mg/week) 3.75 (0.63–5.00) 5.00 (5.00–7.50) p= 0.039
Sulfasalazine (g/day) 10.00 (1.88–21.88) 22.50 (11.25–25.00) p= 0.040
Hydroxychloroquine (mg/day) 0.00 (0.00–0.00) 0.00 (0.00–2.00) p= 0.014
0.00 (0.00–0.00) 400.00 (0.00–400.00) p< 0.001
I
M s) we
b
a
y
(
4
i
t
p
w
t
a
a
f
o
s
m
T
a
g
a
[
d
T
w
a
O
a
w
o
T
C
I
A
G
P
P
E
I
N
K
(
EQR: interquartile range.
ann-Whitney U test (quantitative variables) and Chi2 test (qualitative variable
etween groups T and R concerning Eos or IgE. Controls had
similar gender distribution (p = 0.058, Mann-Whitney U) but
ounger age than groups T (p < 0.001, Mann-Whitney U) and R
p < 0.001, Mann-Whitney U).
. Discussion
An increased prevalence of sensitisation to airborne allergens
n RA patients treated with anti-TNF was found, suggesting
hat pharmacological attenuation of RA with anti-TNF may
redispose to atopy.
To our knowledge no similar studies in RA patients treated
ith anti-TNF have been performed. This is the first observa-
ion of such finding and is consistent with previous reports of
topic dermatitis following anti-TNF therapy for RA [15,16]Please cite this article in press as: Machado P, et al. Increased prevalence
anti-TNF. Joint Bone Spine (2009), doi:10.1016/j.jbspin.2009.01.007
nd psoriasis [17]. Also consistent with our report are the
act that Th2 cells down-regulate IL-1 and TNF in a variety
f experimental conditions [18-20], studies in animal models
uggesting that Th2 cytokines attenuate Th1-dependent autoim-
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omparison between groups of RA patients and controls regarding age, prevalence of
gE (IgE).
RA patients with anti-TNF
(group T, N = 20)
ge – years, median (IQR) 54.50 (50.25–61.50)
ender – female, N (%) 18 (90.00)
revalence of allergic disease – N (%) 11 (55.00)
ositive SPT – N (%) 14 (70.00)
os – per mm 3, median (IQR) 165.00 (97–296.25)
gE – U/ml, median (IQR) 18.00 (18.00–65.75)
P: Not performed; IQR: interquartile range.
ruskal-Wallis test (quantitative variables, when comparing three groups), Mann-Wh
qualitative variables) were used.
lements is bold represent statistical significant values.re used.
une disorders[21-23] and published data suggesting that a
h2 response protects against or limits the development of Th1
utoimmune conditions [24,25]. Sensitisation to airborne aller-
ens, as shown by positive SPT, is an evidence of atopy and is
ssociated with an increased risk of allergic disease over time
8].
We did not find any difference in the prevalence of allergic
isease when comparing RA patients with and without anti-
NF therapy and controls. The prevalence of positive SPT
as also similar between RA patients without anti-TNF ther-
py and controls. These results are consistent with the study of
’Driscoll et al. [26], who found a similar incidence of atopy,
s determined by history or SPT, when comparing 40 subjects
ith RA to age-matched controls. They also found that two
f 266 atopic subjects followed in an allergy clinic had RA, aof allergic sensitisation in rheumatoid arthritis patients treated with
revalence rate similar to that of RA in the general population.
imilarly, Hassan et al. [27], studying 100 patients with RA and
0 controls, also reported no differences between the groups in
topy as assessed by SPT. Olsson et al. [28] found no clear asso-
allergy, positive SPT, eosinophil peripheral blood count (Eos) and serum total
RA patients without
anti-TNF (group R, N = 20)
Controls (group C,
N = 60)
p-value
58.00 (42.25–69.75) 36.00 (28.25–44.75) < 0.001
17 (85.00) 40 (66.70) 0.058
7 (35.00) 22 (36.70) 0.307
7 (35.00) 22 (36.70) 0.024
139.00 (87.50–180) NP 0.229
18.00 (18.00–18.00) NP 0.242
itney U test (quantitative variables, when comparing two groups) and Chi2 test
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iation between RA and atopy in a study with 263 cases and
41 controls based on data from a postal questionnaire followed
y determination of serum specific IgE to common allergens,
lthough the same authors found a trend towards a decrease in
topic disease in patients with RA in a previous retrospective
tudy which included 282 cases and 507 controls [29].
In contrast, two questionnaire-based studies suggested a
ower prevalence of self-reported atopy in cohorts of RA
atients. Hilliquin et al. [30] compared 173 consecutive RA
atients to age and sex-matched controls and found, irrespective
f treatment for RA, a decreased cumulative incidence and point
revalence of atopy. Rudwaleit et al. [31] analysed 728 subjects
ith RA from the database of a university outpatient clinic and
00 controls comprised of a combination of hospital staff mem-
ers and elderly patients with osteoporosis. In this study, the
revalence of atopic disorders globally and allergic rhinitis in
articular was decreased in the RA subjects. Interestingly, a sub-
nalysis of the data found lower severity of RA among those sub-
ects who presented with atopic disease prior to the onset of RA
ompared to patients in whom RA preceded the atopic disorder.
The studies by Hilliquin et al. [30] and Rudwaleit et al. [31]
re supported by a Dutch retrospective cohort study from Ver-
oef et al. [32] which showed that the prevalence of allergic
hinitis in RA patients was about half of that in controls. Further-
ore, RA was less severe in patients suffering also from allergic
hinitis than in RA patients without allergic rhinitis, suggesting
hat atopy affects not only the incidence but also the severity
f RA. In this study, peripheral blood mononuclear cells from
atients with both diseases secreted less IFN- in vitro during
ollen season than the corresponding cells of patients with RA
ut no allergic rhinitis. Once the pollen season was finished,
he levels of IFN- were similar in the two groups of patients.
n summary, despite their limitations, these studies suggest that
topy is decreased in patients with RA compared to controls and
hat among those patients with both diseases, the severity of RA
s decreased.
Demographic characteristics in the two RA patients’ groups
groups R and T) were similar, namely age and gender distri-
ution, disease activity and inflammatory markers, supporting
heir similarity except for the anti-TNF therapy. However, our
esults must be interpreted in the light of a few limitations. Our
ain objective was to compare the prevalence of sensitization
o airborne allergens and allergic disease in patients with and
ithout anti-TNF treatment; as this prevalence has never been
electively reported in these two subgroups of RA patients, sam-
le size calculation could not be performed. However, taking
nto account the reported prevalence of allergic disease in the
A population as a whole and in healthy controls, our sample
ay have been too small and possibly underpowered to detect
ignificant differences. The differences regarding sulfasalazine
nd hydroxychloroquine were predictable, since the majority of
A patients withdrew these drugs once they started anti-TNF
herapy. Methotrexate and prednisolone could have influencedPlease cite this article in press as: Machado P, et al. Increased prevalence
anti-TNF. Joint Bone Spine (2009), doi:10.1016/j.jbspin.2009.01.007
he results, although given the small differences between groups
and T regarding the dosage and the low doses of prednisolone
all patients receiving less than or equal to 7.5 mg/day, a widely
ccepted inferior cut-off for the immunosuppressive effect of
g
f
a PRESS
pine xxx (2009) xxx–xxx
orticosteroids [33]), we do not consider these differences to
epresent a major limitation.
The controls were randomly selected, without a matching
rocedure designed to prevent factors, such as age, occupation
nd environment, from affecting the expression of atopy, and that
ould have represented a selection bias. However, despite birth
ohort [34] and longitudinal [35] studies showing an increase
n allergic sensitisation and symptoms overtime in a consid-
red group of people, in cross-sectional studies the prevalence
f allergic diseases has been described as being lower in older
eople [36]. The controls in our study were younger than cases;
herefore, the influence of this factor may have been minor.
upporting the validity of our control group is the fact that the
revalence of atopy and allergic disease, as assessed by the SPT
nd questionnaire, was similar to that reported in the general
opulation [37,38].
Recent observations challenge the validity of the long-
tanding Th1/Th2 paradigm [39]. Additional lymphocyte
ubsets, such as Th17 cells and regulatory T cells, as well as
ovel soluble factors have been recognised, providing a new
rism through which to examine the intersection of autoimmune
nd allergic disease [40]. Still, in a recent review of the epi-
emiological and mechanistic literature about the nexus between
topic disease and autoimmunity, Rabin and Levinson [41] pre-
ented a model whereby active Th1 inflammation may suppress
he development of atopy, and atopy may suppress the severity
ut not necessarily the onset of autoimmunity. These authors also
raw our attention to the fact that this discussion may help to pre-
ict or interpret unexpected consequences of novel agents used
o target autoimmune or atopic disorders, i.e. therapies targeting
h1- or Th2-specific responses may trigger or reveal underlying
topy or autoimmunity respectively.
Finally, there are differences from the molecular point of
iew and the mechanisms whereby each different anti-TNF
rug acts are not entirely equal [9]. Infliximab is a chimeric
onoclonal antibody and adalimumab is a human recombi-
ant monoclonal IgG1 antibody; they bind both to soluble and
embrane-bound TNF. Etanercept, a fusion protein consisting
f the extracellular ligand of the p75 TNF receptor combined
ith the Fc portion of human IgG1, binds soluble and, to a
esser degree, membrane-bound TNF and also lymphotoxin-
(TNF-). Although infliximab binds both monomeric and
rimeric (bioactive) TNF, it is postulated to cause cell lysis
ia antibody-dependent, cell mediated cytotoxicity or via com-
lement activation. In our study only two patients were treated
ith etanercept. The use of different anti-TNF drugs should
e taken into account in future studies about the prevalence of
topy in anti-TNF treated patients. The biologic effects of the
oluble receptor construct and monoclonal antibodies may not
e the same, as demonstrated by the higher incidence and ear-
ier occurrence of tuberculosis with infliximab and adalimumab
han with etanercept, or by the lack of efficacy of etanercept
n granulomatous diseases, such as Crohn’s disease, Wegener’sof allergic sensitisation in rheumatoid arthritis patients treated with
ranulomatosis and sarcoidosis (with a possible triggering effect
or the last).
In summary, an increased prevalence of sensitisation to
irborne allergens in RA patients treated with anti-TNF was
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ound, suggesting that pharmacological attenuation of RA with
nti-TNF may predispose to atopy. The clinical impact of
he positive SPT following anti-TNF initiation has now to be
ssessed.
Further studies are required to clarify the relationship
etween RA, atopy and anti-TNF therapy, and to identify the
actors, namely the genetic background, environmental factors,
ovel soluble factors and additional lymphocyte subsets (such
s Th17 cells and Tregs) [39-41] affecting the expression of RA
nd atopy. In the future, as clinical testing of selective thera-
ies for autoimmune disorders progress towards larger trials, it
ould be prudent to monitor for manifestations of atopy and
ontinue post-marketing monitoring of currently and futurely
icensed biologic drugs.
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